Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer

Glioblastoma multiforme: Pathogenesis and treatment

(2015) Constantinos Alifieris et al.   PHARMACOLOGY & THERAPEUTICS

Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: A pooled analysis of topotecan second-line trials

(2014) Andrea Ardizzoni et al.   EUROPEAN JOURNAL OF CANCER

Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

(2014) E. Basch et al.   JNCI-Journal of the National Cancer Institute

Efficacy and Safety of Oral Topotecan and Bevacizumab Combination as Second-Line Treatment for Relapsed Small-Cell Lung Cancer: An Open-Label Multicenter Single-Arm Phase II Study

(2013) David R. Spigel et al.   Clinical Lung Cancer

Combination of three cytotoxic agents in small-cell lung cancer

(2012) G. P. Stathopoulos et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A Systematic Analysis of Efficacy of Second-Line Chemotherapy in Sensitive and Refractory Small-Cell Lung Cancer

(2012) Taofeek K. Owonikoko et al.   Journal of Thoracic Oncology

Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: A phase II multicenter study of the Hellenic Oncology Research Group

(2012) Giannis Mountzios et al.   LUNG CANCER

Cisplatin, Irinotecan, and Bevacizumab for Untreated Extensive-Stage Small-Cell Lung Cancer: CALGB 30306, a Phase II Study

(2011) Neal E. Ready et al.   JOURNAL OF CLINICAL ONCOLOGY

A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease

(2010) P. Zatloukal et al.   ANNALS OF ONCOLOGY

Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer

(2010) Suresh S. Ramalingam et al.   CANCER

Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer

(2010) Nikolaos Xenidis et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer

(2010) David R. Spigel et al.   Journal of Thoracic Oncology

Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Lung Cancer: A Systematic Review with Meta-Analysis

(2010) Ping Zhan et al.   Journal of Thoracic Oncology

A Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated Extensive-Stage Small Cell Lung Cancer

(2010) Jingwei Jiang et al.   Journal of Thoracic Oncology

Paclitaxel Plus Bevacizumab in Patients with Chemosensitive Relapsed Small Cell Lung Cancer: A Safety, Feasibility, and Efficacy Study from the Hoosier Oncology Group

(2010) Shadia Jalal et al.   Journal of Thoracic Oncology

Myelotoxicity of oral topotecan in relation to treatment duration and dosage: a phase I study

(2009) George P. Stathopoulos et al.   ANTI-CANCER DRUGS

Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124

(2009) Primo N. Lara et al.   JOURNAL OF CLINICAL ONCOLOGY

Tracheoesophageal Fistula Formation in Patients With Lung Cancer Treated With Chemoradiation and Bevacizumab

(2009) David R. Spigel et al.   JOURNAL OF CLINICAL ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer

(2008) Athanasios G. Pallis et al.   LUNG CANCER

Prognostic and predictive value of vascular endothelial growth factor and its soluble receptors, VEGFR-1 and VEGFR-2 levels in the sera of small cell lung cancer patients

(2008) Zeki Ustuner et al.   MEDICAL ONCOLOGY